
CLAIMS

1. An aqueous pharmaceutical formulation for topical administration comprising delgocitinib dissolved in the aqueous phase comprising
- the compound of formula (I)



acidifying agents and one or more of a pharmaceutically acceptable excipients selected from:
- a base,
- surfactants, emulsifiers, stabilizers,
- pH regulators, buffers
- preservatives,
- antioxidants,
- chelating agents,

and
- purified water.

2. The pharmaceutical formulation according to claim 1, wherein the base is liquid paraffin in an amount from about 50 mg/g to about 500 mg/g.

3. The pharmaceutical formulation according to any one of claims 1-2, wherein the surfactants, emulsifiers, or stabilizers is cetostearyl alcohol which is present in an amount from about 20 mg/g to about 100 mg/g.

4. The pharmaceutical formulation according to any one of the claims 2-3, wherein the surfactants, emulsifiers, or stabilizers is macrogol cetostearyl ether which is present in an amount from about 9 mg/g to about 25 mg/g.

5. The pharmaceutical formulation according to claim 1, wherein the base is liquid paraffin present in an amount from about 75 mg/g to about 300 mg/g and the surfactants, emulsifiers, or stabilizers is cetostearyl alcohol present in an amount from

about 40 mg/g to about 80 mg/g, and macrogol cetostearyl ether present in an amount from about 15mg/g to about 20 mg/g.

6. The pharmaceutical formulation according to claim 5, wherein the liquid paraffin is present in an amount from about 100 mg/g, the cetostearyl alcohol is present in an amount from about 72 mg/g, and the macrogol cetostearyl ether is present in an amount from about 18 mg/g.

7. The pharmaceutical formulation according to any one of the preceding claims 1-6, wherein the buffer, pH regulator is one or more of a phosphate or citrate salt, sodium acetate, sodium carbonate, sodium citrate dihydrate, hydrochloric acid or mixtures thereof.

8. The pharmaceutical formulation according to claim 7, wherein the phosphate or citrate salt is citric acid monohydrate in an amount of from about 0.5 mg/g to about 4 mg/g.

9. The pharmaceutical formulation according to claim 8, wherein the phosphate or citrate salt is sodium citrate dihydrate in an amount of from 0 mg/g to about 1 mg/g.

10. The pharmaceutical formulation according to any one of the claims 1-9, wherein the preservative is benzyl alcohol in an amount from about 7 mg/g to about 13 mg/g.

11. The pharmaceutical formulation according to any one of claims 1-10, wherein the preservative is benzyl alcohol in an amount from about 9 mg/g to about 11 mg/g.

12. The pharmaceutical formulation according to any one of the claims 1-11, wherein the antioxidant is butylhydroxy anisole is in an amount of from about 0.05 mg/g to about 0.3 mg/g.

13. The pharmaceutical formulation according to any one of the claims 1-12, wherein the chelating agent is disodium edetate in an amount from about 0.05 mg/g to about 1.5 mg/g.

14. The pharmaceutical formulation according to any one of the claims 1-13, wherein the acidifying agent is hydrochloric acid in an amount from 0 mg/g to about 25 mg/g.

15. The pharmaceutical formulation according to any one of the claims 1-14, wherein the acidifying agent is hydrochloric acid in an amount from 10 mg/g to about 20 mg/g.

16. The pharmaceutical formulation according to any one of the claims 1-14, wherein the purified water is present in an amount from about 500 mg/g to about 900 mg/g.

17. The pharmaceutical formulation according to any one of the claims 1-15 wherein the compound of formula (I) is present in an amount of 1 mg/g, 3 mg/g, 8 mg/g, or 20 mg/g.

18. The pharmaceutical formulation according to any one of the claims 1-16 wherein the compound of formula (I) is present in an amount of 20 mg/g.

19. A pharmaceutical composition according to any one of claims 1-17, wherein the pH of the water phase is 4.0-4.4.

20. The pharmaceutical formulation according to claim 1 comprising the compound of formula (I), 20 mg/g; liquid paraffin, 100 mg/g; cetostearyl alcohol, 72 mg/g; macrogol cetostearyl ether, 18 mg/g; benzyl alcohol, 10 mg/g; citric acid monohydrate, 1 mg/g; butylhydroxy anisole, 0.2 mg/g; disodium edetate, 0.6 mg/g; 3M hydrochloric acid, 17.7 mg/g; and purified water, 760 mg/g.

21. The pharmaceutical formulation for topical administration comprising the compound of formula (I), 8 mg/g,paraffin liquid, 100 mg/g, cetostearyl alcohol, 72 mg/g, macrogol cetostearyl ether 18 mg/g, benzyl alcohol, 10 mg/g, citric acid monohydrate, 1.0 mg/g, butylhydroxy anisole, 0.2 mg/g, disodium edetate, 0.6 mg/g, 3M hydrochloric acid, 6.43 mg/g, and purified water, 784 mg/g.

22. The pharmaceutical formulation according to any one of the claims above wherein the formulation is a cream.